Journey Advisory Group LLC Grows Position in Medtronic PLC $MDT

Journey Advisory Group LLC lifted its position in Medtronic PLC (NYSE:MDT) by 2,312.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 62,121 shares of the medical technology company’s stock after purchasing an additional 59,546 shares during the period. Journey Advisory Group LLC’s holdings in Medtronic were worth $4,901,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Anfield Capital Management LLC boosted its holdings in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new position in Medtronic in the 4th quarter worth about $27,000. Acumen Wealth Advisors LLC bought a new position in Medtronic during the fourth quarter valued at approximately $29,000. Imprint Wealth LLC bought a new stake in Medtronic in the 3rd quarter worth approximately $31,000. Finally, Basepoint Wealth LLC bought a new stake in Medtronic in the 4th quarter worth approximately $32,000. 82.06% of the stock is currently owned by institutional investors.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic outperformed the broader market in the latest session, closing higher as investors focused on the company’s defensive medical-device exposure. Medtronic Advances While Market Declines
• Positive Sentiment: Seventeen analysts have issued targets over the past six months, with a median target of $101, implying additional upside from recent levels. Targets range widely, however, from $83 to $119. Medtronic Analyst Targets and Trading Data
• Neutral Sentiment: Value-focused coverage is comparing MDT with Agilent Technologies, indicating that investors are evaluating Medtronic’s valuation against peers rather than responding to a major new company-specific catalyst. MDT Versus Agilent for Value Investors
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: 998 investors increased holdings while 1,327 reduced positions, including sizable additions by JPMorgan and reductions by Capital Research and UBS. Medtronic Institutional Activity
• Negative Sentiment: Quiver estimated CEO Geoff Martha’s 2026 compensation at $22.9 million, up 7.4% year over year. It also reported eight open-market insider sales and no purchases over the past six months, which may raise governance and confidence concerns. Medtronic CEO Compensation and Insider Sales
• Negative Sentiment: BTIG reaffirmed a “buy” rating but set a $91 price target, below recent trading levels, signaling limited near-term upside in that analyst’s view. BTIG Reaffirms Medtronic Buy Rating

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.26% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on MDT shares. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research report on Thursday, June 4th. Stifel Nicolaus set a $80.00 target price on Medtronic in a report on Wednesday, June 3rd. Truist Financial cut their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a report on Thursday, June 4th. BTIG Research restated a “buy” rating and issued a $91.00 price target on shares of Medtronic in a research report on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $101.00 price objective on shares of Medtronic in a research note on Wednesday, June 17th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.83.

Medtronic Stock Performance

NYSE:MDT opened at $92.22 on Wednesday. The stock has a 50-day moving average price of $83.60 and a 200 day moving average price of $86.13. The stock has a market capitalization of $118.04 billion, a P/E ratio of 24.72, a P/E/G ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic’s dividend payout ratio is currently 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).